TABLE 3.

Distribution of general characteristics of the study group according to the presence of symptoms 1 mo later

	After 1 mo				Test value
	No symptoms		Symptoms		P
	N	%	N	%
Gender
Female	41	47.7	117	51.1	.589
Male	45	52.3	112	48.9
Age
<65	78	90.7	192	83.8	.121
≤65	8	9.3	37	16.2
Thorax CT
No	48	55.8	60	26.2	<.001
Ground‐glass opacities	31	36.0	129	56.3
Ground‐glass opacities and thrombus	—	—	4	1.7
Consolidation	5	5.8	25	10.9
Consolidation +ground‐glass opacities	2	2.3	10	4.4
nodular infiltration	—	—	1	0.4
Chest X‐rays
Normal	48	55.8	60	26.2	<.001
Infiltration	38	44.2	169	73.8
Treatment
Favipiravir	45	52.3	140	61.1	.004
Favipiravir and Hydroxychloroquine	9	10.5	43	18.8
Hydroxychloroquine	32	37.2	46	20.1
Smoking behavior
Non smoker	46	53.5	151	65.9	.117
Ex‐smoker	17	19.8	36	15.7
Current smoker	23	26.7	42	18.3
Treatment place
Hospital	8	9.3	86	37.6	.001
Home	78	90.7	143	62.4
Comorbidities
No	68	79	114	49	<.001
Yes	18	21	115	51

X² test was used.

Abbreviation: CT, computed tomography.